Compare Neurocrine Biosciences Inc (NBIX) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Global X SuperDividend ETF — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Global X SuperDividend ETF trades at $24.98. Which is the better fit depends on your goals.
| NBIX | SDIV | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $185.50 | $26.34 |
52-Week Low | $123.10 | $22.90 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
SDIV trades at $25.07, down 0.16% with a bullish technical signal from moving averages. The ETF maintains a consistent $0.18 monthly dividend payment schedule through mid-2026, providing income stability. Recent news highlights SDIV's 9.29% yield and diversification benefits away from tech-heavy portfolios, though questions remain about dividend sustainability.
The outlook balances high income generation against sustainability concerns. Key opportunities include attractive yield in a low-rate environment and non-tech diversification, while risks center on dividend coverage and sensitivity to global economic conditions. Technical strength supports near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
